Rezolute (RZLT) Competitors $6.59 +0.09 (+1.43%) As of 03:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RZLT vs. TARS, IRON, HRMY, MESO, CGON, ADPT, VCEL, BEAM, SRPT, and ARQTShould you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Tarsus Pharmaceuticals (TARS), Disc Medicine (IRON), Harmony Biosciences (HRMY), Mesoblast (MESO), CG Oncology (CGON), Adaptive Biotechnologies (ADPT), Vericel (VCEL), Beam Therapeutics (BEAM), Sarepta Therapeutics (SRPT), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. Rezolute vs. Its Competitors Tarsus Pharmaceuticals Disc Medicine Harmony Biosciences Mesoblast CG Oncology Adaptive Biotechnologies Vericel Beam Therapeutics Sarepta Therapeutics Arcutis Biotherapeutics Rezolute (NASDAQ:RZLT) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership. Do analysts rate RZLT or TARS? Rezolute currently has a consensus price target of $12.20, suggesting a potential upside of 84.57%. Tarsus Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 22.87%. Given Rezolute's stronger consensus rating and higher probable upside, research analysts plainly believe Rezolute is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of RZLT or TARS? 83.0% of Rezolute shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 18.4% of Rezolute shares are held by company insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is RZLT or TARS more profitable? Rezolute has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -31.13%. Tarsus Pharmaceuticals' return on equity of -32.36% beat Rezolute's return on equity.Company Net Margins Return on Equity Return on Assets RezoluteN/A -70.09% -63.08% Tarsus Pharmaceuticals -31.13%-32.36%-21.04% Which has more risk and volatility, RZLT or TARS? Rezolute has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Does the media prefer RZLT or TARS? In the previous week, Tarsus Pharmaceuticals had 12 more articles in the media than Rezolute. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 2 mentions for Rezolute. Rezolute's average media sentiment score of 1.77 beat Tarsus Pharmaceuticals' score of 0.98 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tarsus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, RZLT or TARS? Rezolute has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRezoluteN/AN/A-$68.46M-$1.15-5.75Tarsus Pharmaceuticals$182.95M12.52-$115.55M-$2.33-23.29 SummaryRezolute beats Tarsus Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Rezolute News Delivered to You Automatically Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RZLT vs. The Competition Export to ExcelMetricRezoluteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$575.24M$3.13B$5.72B$9.77BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-5.7520.9330.9025.26Price / SalesN/A231.60403.8188.28Price / CashN/A41.5625.2228.45Price / Book3.029.749.516.00Net Income-$68.46M-$54.74M$3.26B$265.34M7 Day Performance11.28%7.94%4.48%2.84%1 Month Performance22.63%7.52%5.19%1.58%1 Year Performance55.90%17.41%31.75%25.40% Rezolute Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RZLTRezolute3.1945 of 5 stars$6.61+1.7%$12.20+84.6%+53.3%$575.24MN/A-5.7540Positive NewsTARSTarsus Pharmaceuticals1.818 of 5 stars$50.07+4.6%$66.67+33.1%+111.0%$2.02B$182.95M-21.4950IRONDisc Medicine3.361 of 5 stars$58.59+1.0%$95.73+63.4%+24.9%$2.01BN/A-13.1130News CoverageAnalyst ForecastInsider TradeHRMYHarmony Biosciences4.5161 of 5 stars$34.80+1.8%$51.00+46.6%+5.5%$1.97B$714.73M11.23200MESOMesoblast1.913 of 5 stars$14.70-2.2%$18.00+22.4%+144.0%$1.92B$5.90M0.0080CGONCG Oncology1.3559 of 5 stars$23.94-3.7%$55.30+131.0%-24.9%$1.89B$1.14M-13.5361ADPTAdaptive Biotechnologies2.4383 of 5 stars$12.15-0.4%$12.38+1.9%+170.0%$1.86B$178.96M-14.82790VCELVericel2.4564 of 5 stars$35.43-2.2%$60.33+70.3%-21.6%$1.83B$237.22M295.27300News CoveragePositive NewsBEAMBeam Therapeutics2.3609 of 5 stars$17.17-2.6%$48.45+182.2%-27.1%$1.78B$63.52M-3.82510SRPTSarepta Therapeutics4.595 of 5 stars$17.94-1.6%$44.17+146.2%-83.7%$1.78B$1.90B-20.621,372Trending NewsAnalyst ForecastShort Interest ↑ARQTArcutis Biotherapeutics1.6402 of 5 stars$14.19-3.9%$19.80+39.5%+98.9%$1.77B$196.54M-18.92150 Related Companies and Tools Related Companies TARS Alternatives IRON Alternatives HRMY Alternatives MESO Alternatives CGON Alternatives ADPT Alternatives VCEL Alternatives BEAM Alternatives SRPT Alternatives ARQT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RZLT) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access